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Abstract
Objective To assess the effects of different types of
individualised risk communication for patients who
are deciding whether to participate in screening.
Design Systematic review.
Data sources Specialist register of the Cochrane
consumers and communication review group,
scientific databases, and a manual follow up of
references.
Selection of studies Studies were randomised
controlled trials addressing decisions by patients
whether or not to undergo screening and
incorporating an intervention with an element of
“individualised” risk communication—based on the
individual’s own risk factors for a condition (such as
age or family history).
Outcome measures The principal outcome was
uptake of screening tests; further cognitive and
affective measures were also assessed to gauge
informed decision making.
Results 13 studies were included, 10 of which
addressed mammography programmes.
Individualised risk communication was associated
with an increased uptake of screening tests (odds ratio
1.5, 95% confidence interval 1.11 to 2.03). Few
cognitive or affective outcomes were reported
consistently, so it was not possible to conclude
whether this increase in the uptake of tests was related
to informed decision making by patients.
Conclusions Individualised risk estimates may be
effective for purposes of population health, but their
effects on increasing uptake of screening programmes
may not be interpretable as evidence of informed
decision making by patients. Greater attention is
required to ways of developing interventions for
screening programmes that can achieve this.
Introduction
Various tests and procedures can be used for
screening—to identify individuals and groups at “high
risk” of various diseases or conditions. Many of these
tests and procedures form part of screening pro-
grammes whose purposes are usually to reduce
morbidity in the population but which may not always
be effective for individuals. At the individual level
several issues are important. These include the chances
of detecting and preventing disease, or of false positive
or negative tests with their important consequences in
terms of tests or treatments to be undergone, or
morbidity “unnecessarily” suffered.1 These chances of
the potential harms and benefits must be considered
by individuals making informed decisions about
whether or not to undergo screening tests in health
care.2
Understanding of how best to present and discuss
risks and benefits of health care in general, and screen-
ing in particular, for an individual is still limited. Some
screening programmes provide information about
population or “average” risks of contracting a disease;
these often simply try to motivate people to attend for
tests that are perceived by authorities to be in their own
or the population’s best interests.3 Other programmes
attempt to provide information that is more personally
relevant to the patient in question. We describe this as
“individualised risk communication.”4 This may be
based on the individual’s own risk factors for a
condition (such as age or family history). In some cases
it is calculated from an individual’s risk factors by using
formulas derived from epidemiological data, such as
the Gail formula for risk of breast cancer.5 The
information itself may then be represented as an abso-
lute risk or as a risk score, or categorised—for example,
into high, medium, or low risk groups. It may be less
detailed, entailing a listing—for example, of a patient’s
risk factors as a focus for discussion and intervention.
In these scenarios it is generally anticipated that
because the information is thought to be more
pertinent individualised risk communication is more
likely to be useful in making a decision about whether
or not to participate in screening. But awareness is
growing that decisions about screening can be
influenced by the way in which information on risk is
presented and that this may not necessarily be
evidence of informed decision making.6 7 Raffle warns
that harm to uninformed participants leads to anger,
bitterness, and potentially litigation.8 The social and
psychological costs of screening therefore need to be
assessed.9
Reviews of mass risk communication (to popula-
tions), primarily from the discipline of environmental
health10–12 and from narrow clinical fields such as
familial cancer, are available.13 The effects of communi-
cating risk in screening are not well understood to date.
We undertook a systematic review to evaluate these
effects, in particular to assess the effects of providing
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individual risk estimates in comparison with more
general information on risk, and to see whether there
is evidence that these contribute to informed decision
making by consumers. This report summarises a
Cochrane review published earlier this year.14
Methods
Two reviewers assessed for inclusion and extracted
data on trial quality, the intervention, and relevant out-
come data.We undertook meta-analysis where feasible.
This review used standard methods based on guidance
from the Centre for Reviews and Dissemination (UK)15
and from the Cochrane Collaboration’s consumers
and communication review group.
Types of studies
We included only randomised controlled trials. We did
not exclude studies that were not by intention to treat,
but their lower methodological quality is reflected in
their method scores and the weight attached to their
findings tempered accordingly.16
Types of participants
We included studies of people facing real decisions
(not hypothetical exercises) about whether to undergo
screening (presumptive identification of unrecognised
disease or defect by the application of tests or other
procedures, which can be applied rapidly). This could
therefore include individuals making decisions alone
or on another’s behalf (for a young child), or couples
making decisions together.
The screening activities entailed investigations per-
formed by or provided by health professionals. Exam-
ples could include mammography, cervical Pap
smears, colorectal screening, screening for prostatic
cancer (PSA test), antenatal screening, genetic screen-
ing (including breast cancer gene testing), screening
for high cholesterol and cardiovascular risk, and
neonatal screening.
Types of interventions
The interventions were providing information on indi-
vidualised risk: firstly, individualised risk score or indi-
vidual actual risk information (for example, calculated
risk of breast cancer over the next 10 years17); secondly,
categorisations of risk status based on these estimates
(for example, high, medium, or low risk status, such as
for colorectal cancer18); or, thirdly, discussion of
personal risk factors relevant to the screening decision
(the individual’s own characteristics are taken into
account in assessing their actual risk or heightened risk
status relative to others—examples include risk factors
for breast or prostate cancer19 20 that are relevant to the
individual).
We compared interventions providing information
on individualised risk with those providing infor-
mation on generalised risk, including average or popu-
lation risk estimates (such as risk of breast cancer or
cervical cancer), general information on risk factors,
and general encouragement to acknowledge risks or
change risk behaviour. We rejected studies if they
simply evaluated health education or promotion to
reduce risk factors or increase adherence to screening,
without discussing the risks and benefits of undergoing
or not undergoing screening.
Types of outcome measures
We extracted outcome data if available in the following
areas21 22): firstly, cognitive outcomes: knowledge of risk,
accurate risk perception; secondly, affective outcomes:
anxiety, satisfaction with decisions made, decisional
conflict, anxiety, intention to take up screening; thirdly,
behavioural outcomes: uptake of tests, adherence to
choice regarding screening programme, “appropriate”
uptake; and fourthly, health status outcomes—for
example specific status measures or quality of life meas-
ures such as the short form questionnaire 36 (SF-36).
Search strategy for identification of studies
Two reviewers (SU and AE) searched the specialised
register of the Cochrane consumers and communica-
tion review group, Medline, EMBASE, CancerLit,
CINAHL, ClinPSYC, and the Science Citation Index
Expanded. The search strategies included three layers
of search terms—keywords and medical subject
headings (MeSH)—to identify articles about screening
that included counselling or education on risk specifi-
cally. Databases were searched in Ovid (www.ovid.com)
from 1985 onwards, as preceding years have low yields
in this field.23 For the search strategies see appendix 1
on bmj.com.
A manual follow up of references comprised the
most frequently encountered journal (Preventive Medi-
cine), contacting seven most frequently encountered
authors (B K Rimer, C Lerman, M D Schwartz, V
Champion, M W Kreuter, C S Skinner, and R Bastani)
and citation index searches for these authors. We also
checked other prominent reviews and a trials register
in the field.24 25
Methods of the review
Two reviewers (AE and SU) independently selected
publications from search outputs (titles and abstracts).
Disagreements were resolved by discussion. In cases of
doubt papers were retrieved in full for final assessment,
including circulation of rejected papers to other mem-
bers of the group to review the decision.
Data extraction
AE and SU extracted the data on to a template cover-
ing country of origin, group of health professionals
involved, screening programme, group of patients
involved, setting, sample size, and key outcomes. We
extracted data on differences in baseline risk to assess
effect modifiers. We extracted data on the nature and
design of the intervention, including the type of
individualised risk communication in the main
intervention (see types of interventions). Outcome data
comprised the absolute changes in numbers between
groups (for dichotomous variables) and the mean
change and standard deviation of the mean change
(for continuous variables). We also recorded statistical
significance of results. We extracted data to assess the
quality of the study against methodological check-
lists.4 26 The checklist by Edwards et al assesses the
quality of the trial and its report in the literature, but
does not, for example, score on blinding of participants
as it is often not feasible to do so in trials of risk com-
munication.4 Differences in assessment of publications
were resolved by discussion between the assessors.
Data combination
We first examined studies for qualitative synthesis. We
then applied standard statistical methods for the
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consumers and communication review group to com-
bine data by using MetaView where feasible, subject to
assessment of homogeneity. We calculated odd ratios
for dichotomous variables, and weighted mean
differences for continuous outcomes. Sensitivity analy-
ses entailed analysing different sections of the data—for
example, according to different screening programme
or studies based only on participants at high risk (as
defined in the studies themselves, due to particular risk
factors) rather than people at average risk. We also
used the categorisation of individualised risk commu-
nication into three levels of detail given to consumers,
to examine for evidence of different effect from
heterogeneous groups of interventions.
Insufficient data were provided in many studies to
enable (raw) data entry into MetaView. In view of the
heterogeneity of the studies in terms of the screening
programmes addressed, participants, and design of
intervention we used a random effects model (giving a
more conservative confidence interval on estimates of
effect sizes).
Results
Description of studies
Thirteen studies met the inclusion criteria (please note
that Lerman et al 199532 and Schwartz et al 199936 arise
from the same study). Ten of these described interven-
tions for mammography screening programmes or in
relation to breast cancer risk and gene testing. Two
addressed screening for (high) cholesterol, and one
each addressed cervical, prostate, and colorectal
screening (some studies covered more than one topic).
Four studies were based on samples of people thought
or known to be at higher risk than average for the
population. Eleven studies were from the United
States. The interventions were delivered by a range of
healthcare professionals, ranging from doctors and
nurses to staff specifically recruited and trained for the
study.
With regard to outcomes reported, 12 studies
measured uptake of screening, but only 10 had reliable
data for meta-analysis. Four measured changes in the
perception of risk and susceptibility. Beyond this there
were only occasional outcomes with reliable data for
extraction. One study reported changes in knowledge
with data that could be extracted, two measured inten-
tions to undergo screening, and two measured
movement across stages of change. We found no
extractable data on costs, “appropriate” uptake, or
health status (other than anxiety).
Some studies were considered closely for inclusion
but were eventually excluded. Broadly these fell into
two groups. Some examined individualised risk
communication but had either no control data or inad-
equate control data for comparison. Others did not
specifically examine individualised risk communica-
tion as a separable intervention effect.
Methodological quality of included studies
The studies were of variable quality, but almost all
method scores were above average for risk communi-
cation studies in health care.4 Although all were
randomised trials, description of allocation conceal-
ment was adequate in two studies, inadequate in one,
and unclear in the remainder.
Review findings and meta-analysis
The table shows principal data on the types of
intervention, outcomes, and method scores of the 13
included studies. Appendix 2 on bmj.com and the
Cochrane review contain further descriptions of the
studies and outcomes.14 Overall we found evidence that
individualised risk communication (whether written,
spoken, or visually presented) was associated with an
increased uptake of screening tests (odds ratio 1.5, 95%
confidence interval 1.11 to 2.03) (figure for data from
random effects models). The study outcomes showed
statistical evidence of heterogeneity. Insufficient data
were available (for example, on knowledge, perceived
risk levels, attitudes to tests, and intentions to take or
actual taking of tests) to assess whether this increase in
test uptake was related to informed decision making.
Effect modifiers
Within this overall increase in uptake we found limited
evidence that more detailed communication of
individualised risk may lead to smaller increases in the
uptake of tests (see figure). For individualised risk com-
munication that used and presented numerical
calculations of risk, the odds ratio for test uptake was
1.22 (0.56 to 2.68). For risk estimates or calculations
that were categorised—for example, into high,medium,
or low strata of risk—the odds ratio was 1.42 (1.07 to
1.88). For risk communication that simply listed
personal risk factors the odds ratio was 1.7 (1.17 to
2.48). Differences between the categories did not reach
significance.
The results for the studies addressing mammogra-
phy showed slightly smaller effects than among the
whole group of studies (odds ratio for mammography
studies 1.13, 0.98 to 1.29). The four studies examining
risk communication in individuals at “higher
risk”19 27 28 32 36 showed larger odds ratios (1.99, 1.52 to
2.6) for uptake of tests than the other studies.
Discussion
Principal findings
Few studies in the field of screening have examined the
effects of communicating individualised risk. Individu-
alised risk communication is associated with higher
uptake of tests, but the evidence that this is necessarily
informed decision making by consumers is insufficient.
We found insufficient studies to assess effect modifiers
reliably, but some evidence showed that effects (on
uptake) were greater among individuals at higher risk
of disease.
Strengths and weaknesses of the review and its
findings
The weaknesses of these data lie in the small number of
studies. Findings or hypotheses arising from these data
require further evaluation when more primary studies
are available. The results are dominated by findings
from the topic area of mammography. Caution is
required in generalising from these results, and
particularly for clinical topics other than mammogra-
phy. Against this, the strength of these data lies in the
fact that the studies have been gleaned from systematic
searches of several key databases and contact with key
authors in the field, and represent a synthesis of the
existing literature base.
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Characteristics of studies included in this review
Study Design Participants Interventions Outcomes
Allocation
concealment Method score Notes
Bastani et al
199927
Randomised
controlled trial
Women aged over 30; breast
cancer in first degree relative;
resident in United States or
Canada
Mailed notification of
individualised risk
assessment and other
theoretically driven
(adherence model) materials
tailored for women at high
risk
Uptake of mammography
one year after baseline
survey
Unclear 15/22
Champion
199428
Randomised
controlled trial
Women aged ≥35 who had
never had breast cancer;
United States
In-home interviews
conducted by graduate
nursing research assistants.
Discussion about individual
risk factors—susceptibility
intervention—as part of a
belief modifying intervention
Change in beliefs and
knowledge (including
susceptibility scores) after
the intervention;
mammography compliance
one year after the
intervention
Unclear 16/22
Champion
et al 199529
Randomised
controlled trial
Women aged ≥35; not
diagnosed with breast cancer;
United States (analysis of
intervention effect only on
women aged ≥40
Interviews conducted at
home by graduate nursing
students. Discussion about
individual risk
factors—susceptibility
intervention—as part of a
belief modifying intervention
Change in beliefs and
knowledge (including
susceptibility (scores);
mammography compliance;
movement across stages of
change
Unclear 12/22 Raw data for compliance
outcomes not available for
inclusion in meta-analysis;
other results included in
appendix 2 on bmj.com
and Cochrane review14
Curry et al
199319
Randomised
controlled trial
Women aged ≥50; newly
enrolled in a health
maintenance organisation
without prior history of breast
cancer or of mammography
use in the previous 12
months; United States
Mailed risk factor
questionnaire plus personal
risk invitation detailing
personal risk factors
Use of mammography
within one year of invitation
Unclear 18/22
Hutchison
et al 199830
Randomised
controlled trial
Patients aged 20-69 years,
from two primary care group
practices; Canada
Risk appraisal questionnaire
(yielding risk score). People
with scores above 2 were
advised to go for screening
Rate of cholesterol testing
during the three months of
follow up
Unclear 14/22
Kreuter et al
199631
Randomised
controlled trial
Patients aged 18-75 from
eight family medical practices;
North Carolina, United States
Mailed health risk
appraisal—risk information
tailored to information given
at baseline questionnaire
Rate of uptake of Pap
smear, mammography, and
cholesterol screeing after
six months in participants
contemplating these
behaviours at baseline
Inadequate 15/22 Multiple outcomes from
overlapping groups of
patients, so single figure
not included in
meta-analysis; separate
figures reported in
appendix 2 on bmj.com
and Cochrane
meta-analysis14
Lee 199118 Randomised
controlled trial,
stratified for previous
screening history
and risk status
Federal employees aged ≥40;
United States
Appraisal of risk of
colorectal—categorised as
high, medium, or low
personal risk
Knowledge, intention to take
test, and uptake
Unclear 16/22
Lerman et al
199532
Randomised
controlled trial
Women aged 35 years and
older with a family history of
breast cancer in a first degree
relative; United States
Counselling for risk of
breast cancer, including
discussion of factors
contributing to heightened
risk and presentation of
individualised risk data
Changes or improvement in
risk comprehension
Adequate 13/22 Additional paper33
addresses effects on
general and breast cancer
specific distress
Lerman et al
199734
Randomised
controlled trial
Women aged 18-75 who had
at least one first degree
relative with breast or ovarian
cancer; United States
Educational session
including a review of
individual risk factors for
breast and ovarian cancers
Changes in risk perception;
testing intentions
Unclear 16/22 No data on taking test in
control group
Myers et al
199920
Randomised
controlled trial
African American men, aged
40-70; patients at the
University of Chicago, United
States
A personalised “pro-record,”
which included a form with
tailored risk factors and
symptoms
“Adherence”—men who
made an office visit for
prostate cancer education
and early detection within a
year
Unclear 15/22
Rimer et al
200117
Randomised
controlled trial
Women in their 40s and 50s,
and members of Blue Cross
Blue Shield (a health
maintenance organisation);
North Carolina, United States
Tailored print and
counselling detailing a
woman’s personal risk
(numerical and graphical) of
breast cancer
Accuracy of risk
perceptions; mammography
uptake
Unclear 18/22
Saywell et al
199935
Randomised
controlled trial
Women aged 50-85,
non-compliant with
mammography guidelines, no
history of breast cancer;
United States
Telephone and in person
counselling including
discussion of personal risk
factors
Mammography compliance
four to six weeks after
counselling
Adequate 12/22
Schwartz et al
199936
Randomised
controlled trial
Women with family history of
breast cancer (first degree
relative of sufferer) aged ≥40;
United States
Risk counselling including
individualised risk figures
Self reported mammography
use one year after
(compared with baseline)
Unclear Follow up to the Lerman
et al 1995 trial
Skinner et al
199437
Randomised
controlled trial,
stratified between
clinics
Female family practice
attenders aged 40-65; United
States
Tailored text re: beliefs,
mammography stages, risk
factors, and barriers
Mammography stage and
uptake
Unclear 15/22
Studies by Bastani et al,27 Curry et al,19 Hutchison et al,28 and Lerman and Schwartz et al32 36 were designated as studies of individuals at higher than average risk.
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The relative paucity of data in the screening area
reflects the difficulties in communicating individual-
ised risk to consumers. The range of clinical topics cov-
ered here is narrow. Calculation or estimation of risk is
dependent on adequate epidemiological data, and fea-
sible means of converting this into information for
individual consumers on the basis of their own risk
factors. Examples include the Gail model for risk of
breast cancer5 and methods for calculating cardiovas-
cular risk,38 but only the latter have permeated into
routine clinical practice. Equivalent epidemiological
research into a broader range of clinical topics is
needed to enable calculation of individualised risk esti-
mates for individuals with these conditions. Then
further evaluation of the effects of providing such
information on individualised risk to consumers would
be possible.
High risk status as an effect modifier
The intervention effects seemed greater among
consumers or patients deemed to be at higher risk than
average.19 27 28 32 36 Thus a “high risk status” of consum-
ers may be an important effect modifier for individual-
ised risk communication, indicating substantial poten-
tial to modify choices made by such people. This may
be a positive opportunity for clinicians to influence
decisions among people with risk factors for a
condition, but equally it could be potentially harmful if
interventions are not introduced carefully.
Informed decision making
Two studies provided the most detailed risk estimates
to patients, but were the only ones to show a reduction
in uptake of tests.17 36 These effects of communicating
risk are consistent with the effects of framing and other
manipulations of data representation in health care7—
that more information, especially information that is
most pertinent to the individual and the decision on
treatment in question, often makes consumers more
wary of the treatments or tests on offer. Provision of a
service may lead patients to perceive that professionals
desire use of the service (in this case uptake of tests)
rather than informed choices by patients. When the
direction of effects is for lower uptake of tests, as in
these two studies,17 36 it implies that information can
have an important effect. This shows that the overall
effect (of increasing uptake) in this review should be
regarded with caution.
Implications for screening programmes
As above, the effects of interventions in this review may
provide positive opportunities for clinicians to
influence decisions among people with risk factors for
a condition, but interventions must be introduced
carefully to avoid harm. The opportunities to mislead
are endless.39 The fact that screening decisions by con-
sumers can be influenced substantially by the type of
information generates tension between individual
health policy (which seeks to enhance informed
decision making) and objectives of population health.
The data in this review indicate that the effects of
informing patients about individualised risk are
variable. In some instances the objectives of population
health might be compromised (by lower uptake). The
cost effectiveness of screening programmes in reduc-
Calculated risk score (numerical) v general information
Hutchinson et al 1998
Rimer et al 2001
Schwartz et al 1999
Subtotal (95% CI)
Test for heterogeneity χ2=25.95, df=2, P<0.001
Test for overall effect z=0.50, P=0.6
75/1544
204/392
148/215
427/2151
Study Personalised risk
n/N
27/1603
231/412
161/215
419/2230
General risk info
n/N
10.4
12.0
10.6
33.0
2.98 (1.91 to 4.65)
0.85 (0.64 to 1.12)
0.74 (0.49 to 1.13)
1.22 (0.56 to 2.68)
Calculated risk score (categorised) v general information
Bastani et al 1999
Lee 1991
Subtotal (95% CI)
Test for heterogeneity χ2=0.62, df=1, P=0.43
Test for overall effect z=2.43, P=0.02
249/382
12/139
261/521
214/371
6/139
220/510
11.9
5.4
17.3
1.37 (1.02 to 1.84)
2.09 (0.76 to 5.75)
1.42 (1.07 to 1.88)
Personal risk factor list v general information
Champion 1994
Curry et al 1993
Myers et al 1999
Saywell et al 1999
Skinner et al 1994
Subtotal (95% CI)
Test for heterogeneity χ2=13.55, df=4, P=0.0089
Test for overall effect z=2.75, P=0.006
117/147
162/413
98/192
68/237
33/76
478/1065
103/153
161/428
64/221
20/110
24/76
372/988
9.5
12.0
10.8
9.2
8.1
49.7
1.89 (1.12 to 3.20)
1.07 (0.81 to 1.41)
2.56 (1.70 to 3.84)
1.81 (1.03 to 3.17)
1.66 (0.86 to 3.23)
1.70 (1.17 to 2.48)
Total (95% CI)
Test for heterogeneity χ2=46.46, df=9, P<0.001
Test for overall effect z=2.63, P=0.008
1166/3737 1011/3728
0.2 1
Favours general Favours personal
5 100.1
100.0 1.50 (1.11 to 2.03)
Weight
(%)
Odds ratio
(95% CI random)
Odds ratio
(95% CI random)
Uptake of test outcomes from 10 studies addressing decisions by patients on whether or not to undergo screening that were used in the
review: random effects meta-analysis
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ing the burden of disease depends on reaching a
threshold level of coverage of the tests in the target
population. Interventions using individualised risk
communication may sometimes limit the ability of a
programme to reach this threshold and sometimes
enhance it.
These tensions between the goals of population
health and individual choices must be recognised.40 An
informed debate should be conducted among the rel-
evant interest groups—government, public health,
clinicians, and particularly patients and their represen-
tative groups—and signs show that this is starting.41
Policy developments could explore whether individu-
ally appropriate choices, which may include choosing
not to take tests, can be accommodated in standards
and assessments of achieving best practice at
population level.
Further research
If informed decision making by consumers is
important, one consequence is that valid instruments
will be needed to show that it has occurred. Some
measures for specific conditions exist, such as the
multidimensional measure of informed choice in
screening for Down’s syndrome.42 It examines the con-
sistency between knowledge, attitudes to tests, inten-
tions, and choices of uptake of tests. Further research
should develop measures for other screening choices,
or whether a generic measure of informed choice for
screening decisions is feasible.
Research should also evaluate individual cognitive
and affective outcomes of interventions using risk
communication. These include decisional conflict,
satisfaction with decision making, and anxiety
measures.43–45 Further intervention studies in this field
need to incorporate such measures into their
evaluations as they address some of the core constructs
that build towards informed decision making by
consumers.
These developments may make the effects of indi-
vidualised risk communication interventions clearer,
both in terms of informed decision making and uptake
of tests. Until such data are available it seems
premature to advocate the use of individualised risk
communication simply on the basis that increased
uptake of screening programmes has been shown.
Conclusions
Communication of individualised risk generally leads
to increased uptake of screening programmes. This
may meet professionally or policy driven agendas in
health care, but it is not yet clear that the increased
uptake is associated with informed decision making by
consumers. Further evaluation of strategies to promote
informed decision making is still required, and this
must include detailed assessment of the cognitive and
affective outcomes that may influence subsequent
behavioural outcomes (namely, uptake of tests).
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What is already known on this topic
Screening programmes are increasingly looking
towards ways of promoting informed choices by
people invited to have tests
Individualised risk communication—using specific
risk estimates based, for example, on the
individual’s own risk factors for a condition (such
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